β-Catenin signaling is a critical event in ErbB2-mediated mammary tumor progression
- PMID: 23720052
- DOI: 10.1158/0008-5472.CAN-12-3925
β-Catenin signaling is a critical event in ErbB2-mediated mammary tumor progression
Abstract
Although ERBB2 amplification and overexpression is correlated with poor outcome in breast cancer, the molecular mechanisms underlying the aggressive nature of these tumors has not been fully elucidated. To investigate this further, we have used a transgenic mouse model of ErbB2-driven tumor progression (ErbB2(KI) model) that recapitulates clinically relevant events, including selective amplification of the core erbB2 amplicon. By comparing the transcriptional profiles of ErbB2(KI) mammary tumors and human ERBB2-positive breast cancers, we show that ErbB2(KI) tumors possess molecular features of the basal subtype of ERBB2-positive human breast cancer, including activation of canonical β-catenin signaling. Inhibition of β-catenin-dependent signaling in ErbB2(KI)-derived tumor cells using RNA interference impaired tumor initiation and metastasis. Furthermore, treatment of ErbB2(KI) or human ERBB2-overexpressing tumor cells with a selective β-catenin/CBP inhibitor significantly decreased proliferation and ErbB2 expression. Collectively, our data indicate that ERBB2-mediated breast cancer progression requires β-catenin signaling and can be therapeutically targeted by selective β-catenin/CBP inhibitors.
©2013 AACR.
Similar articles
-
β-Catenin haploinsufficiency promotes mammary tumorigenesis in an ErbB2-positive basal breast cancer model.Proc Natl Acad Sci U S A. 2017 Jan 31;114(5):E707-E716. doi: 10.1073/pnas.1610383114. Epub 2017 Jan 17. Proc Natl Acad Sci U S A. 2017. PMID: 28096336 Free PMC article.
-
Beta 4 integrin amplifies ErbB2 signaling to promote mammary tumorigenesis.Cell. 2006 Aug 11;126(3):489-502. doi: 10.1016/j.cell.2006.05.047. Cell. 2006. PMID: 16901783
-
Increased erbB3 promotes erbB2/neu-driven mammary tumor proliferation and co-targeting of erbB2/erbB3 receptors exhibits potent inhibitory effects on breast cancer cells.Int J Clin Exp Pathol. 2015 Jun 1;8(6):6143-56. eCollection 2015. Int J Clin Exp Pathol. 2015. PMID: 26261492 Free PMC article.
-
A Wnt-ow of opportunity: targeting the Wnt/beta-catenin pathway in breast cancer.Curr Drug Targets. 2010 Sep;11(9):1074-88. doi: 10.2174/138945010792006780. Curr Drug Targets. 2010. PMID: 20545611 Review.
-
ErbB2 activation and signal transduction in normal and malignant mammary cells.J Mammary Gland Biol Neoplasia. 1996 Apr;1(2):199-206. doi: 10.1007/BF02013643. J Mammary Gland Biol Neoplasia. 1996. PMID: 10887493 Review.
Cited by
-
Mammary cells with active Wnt signaling resist ErbB2-induced tumorigenesis.PLoS One. 2013 Nov 12;8(11):e78720. doi: 10.1371/journal.pone.0078720. eCollection 2013. PLoS One. 2013. PMID: 24265712 Free PMC article.
-
Rheb1-Independent Activation of mTORC1 in Mammary Tumors Occurs through Activating Mutations in mTOR.Cell Rep. 2020 Apr 28;31(4):107571. doi: 10.1016/j.celrep.2020.107571. Cell Rep. 2020. PMID: 32348753 Free PMC article.
-
The expression of β-catenin in different subtypes of breast cancer and its clinical significance.Tumour Biol. 2014 Aug;35(8):7693-8. doi: 10.1007/s13277-014-1975-0. Epub 2014 May 8. Tumour Biol. 2014. PMID: 24801904
-
The glucose transporter GLUT1 is required for ErbB2-induced mammary tumorigenesis.Breast Cancer Res. 2016 Dec 20;18(1):131. doi: 10.1186/s13058-016-0795-0. Breast Cancer Res. 2016. PMID: 27998284 Free PMC article.
-
Inhibition of GSK-3 to induce cardiomyocyte proliferation: a recipe for in situ cardiac regeneration.Cardiovasc Res. 2019 Jan 1;115(1):20-30. doi: 10.1093/cvr/cvy255. Cardiovasc Res. 2019. PMID: 30321309 Free PMC article. Review.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Molecular Biology Databases
Research Materials
Miscellaneous
